DAL BEN, Diego
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.688
EU - Europa 6.796
AS - Asia 4.556
SA - Sud America 570
AF - Africa 198
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 9
Totale 24.845
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.321
CN - Cina 1.824
PL - Polonia 1.721
SG - Singapore 1.360
RU - Federazione Russa 1.326
IT - Italia 1.185
DE - Germania 595
BR - Brasile 473
GB - Regno Unito 435
HK - Hong Kong 378
FR - Francia 370
VN - Vietnam 357
UA - Ucraina 337
CA - Canada 306
SE - Svezia 258
FI - Finlandia 221
KR - Corea 153
ZA - Sudafrica 139
TR - Turchia 132
IE - Irlanda 92
IN - India 88
JP - Giappone 68
NL - Olanda 54
BE - Belgio 40
MX - Messico 40
AR - Argentina 37
BD - Bangladesh 33
ES - Italia 28
EU - Europa 27
AT - Austria 22
IQ - Iraq 18
EC - Ecuador 16
TW - Taiwan 16
CZ - Repubblica Ceca 15
PK - Pakistan 15
LT - Lituania 14
AE - Emirati Arabi Uniti 13
CO - Colombia 12
IR - Iran 12
KE - Kenya 12
RO - Romania 12
RS - Serbia 12
CH - Svizzera 10
PY - Paraguay 10
TN - Tunisia 10
EG - Egitto 9
JO - Giordania 9
SA - Arabia Saudita 9
UZ - Uzbekistan 9
VE - Venezuela 9
DK - Danimarca 8
ID - Indonesia 8
AU - Australia 7
IL - Israele 7
LB - Libano 7
PE - Perù 7
DZ - Algeria 6
PH - Filippine 6
AL - Albania 5
AM - Armenia 5
AZ - Azerbaigian 5
HU - Ungheria 5
MA - Marocco 5
BG - Bulgaria 4
CI - Costa d'Avorio 4
HR - Croazia 4
MY - Malesia 4
NP - Nepal 4
BY - Bielorussia 3
CL - Cile 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
LV - Lettonia 3
NI - Nicaragua 3
NO - Norvegia 3
SI - Slovenia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
GE - Georgia 2
JM - Giamaica 2
KH - Cambogia 2
KW - Kuwait 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BO - Bolivia 1
CM - Camerun 1
DM - Dominica 1
EE - Estonia 1
GD - Grenada 1
GT - Guatemala 1
Totale 24.830
Salva come PNG Salva come JPEG
Città #
Warsaw 1.494
Fairfield 1.295
Ashburn 1.105
Woodbridge 971
Jacksonville 793
Singapore 681
Houston 626
San Jose 593
Chandler 567
Seattle 544
Wilmington 515
Ann Arbor 483
Cambridge 449
Dallas 367
Hong Kong 357
Boardman 354
Beijing 314
Camerino 261
Nanjing 246
Kraków 213
Toronto 202
Los Angeles 190
Council Bluffs 184
The Dalles 154
New York 132
Seoul 127
Johannesburg 124
Helsinki 118
San Mateo 117
Tongling 116
Dearborn 111
Lawrence 111
Princeton 111
Ho Chi Minh City 110
Columbus 109
London 106
Istanbul 104
Lauterbourg 100
Moscow 91
Dublin 90
Ogden 89
Düsseldorf 81
Chicago 75
Buffalo 74
San Diego 73
Shanghai 73
Nanchang 71
Guangzhou 69
St Louis 66
Milan 65
Santa Clara 63
Hanoi 60
São Paulo 59
Lachine 57
Tokyo 53
Munich 51
Frankfurt am Main 50
Dong Ket 49
Tianjin 49
Kunming 46
Edinburgh 44
Shenyang 43
Brussels 39
Orem 39
Jiaxing 38
Rome 38
Hebei 36
Centro 35
Changsha 27
Atlanta 26
Denver 26
Manchester 26
Philadelphia 26
Hangzhou 25
San Francisco 25
Trieste 25
Jinan 23
Phoenix 23
Wuhan 23
Falls Church 22
Poplar 22
Redwood City 22
Amsterdam 21
Hefei 20
Montreal 20
Ningbo 20
Norwalk 20
Redondo Beach 20
Scafati 20
Boston 19
Chennai 19
Nuremberg 18
Stockholm 18
Mexico City 17
Bologna 16
Brooklyn 16
Jinhua 16
Rio de Janeiro 16
Turku 16
Verona 16
Totale 16.989
Salva come PNG Salva come JPEG
Nome #
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 644
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 450
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 403
Overview on Radiolabel-Free in Vitro Assays for GPCRs 399
Pharmacological characterization of the GPR17 receptor dual profile 393
GPR17 receptor modulators and their therapeutic implications: review of recent patents 389
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 384
The G Protein-Coupled Receptor GPR17: Overview and Update 370
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 363
Stabilization of the cyclodecadiene derivative isofuranodiene by silver (I) coordination. Mechanistic and biological aspects 359
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 355
Emerging Roles of Purinergic Signaling in Diabetes 354
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 325
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 299
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 297
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 293
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 289
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 282
P2X7 Receptor as a Therapeutic Target 278
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 274
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 265
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 264
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 264
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 250
Antiproliferative Evaluation of Isofuranodiene on Breast and Prostate Cancer Cell Lines 244
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 244
The P2X7 Receptor in Infection and Inflammation 240
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 240
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 236
Identification of a specific residue that confers BzATP sensitivity to P2X2 receptors 236
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 234
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 234
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 233
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 233
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 232
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 230
New sensible method to quantize the intestinal absorption of receptor ligands 224
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 220
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 219
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 218
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 217
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 217
Antiviral properties of deazaadenine nucleoside derivatives 214
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 213
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 212
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A3 and A2A subtypes 211
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel (18)F-labelled PET tracer targeting P2X7 211
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 210
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 210
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 208
Interaction model for anthracycline activity against DNA topoisomerase II 207
Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site 207
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A2B receptor 205
Adenosine receptor modeling: what does the A2A crystal structure tell us? 204
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 203
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 202
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 202
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 198
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 198
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 196
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 196
Innovative functional cAMP assay: application to the pharmacological characterization of GPR17 195
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 193
Amide bond direction modulates G-quadruplex recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted anthracenedione derivatives 192
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 190
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 189
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 188
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 185
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 184
Functional cAMP assay optimization at CHO cells expressing A2A adenosine receptors and stably transfected with firefly luciferase biosensor 183
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 183
I protocolli operativi nella violenza di genere 178
Synthesis, structure-affinity relationships and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists 177
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 176
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 176
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies 176
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 176
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease 174
DNA Topoisomerase II Structures and Anthracycline Activity: Insights into Ternary Complex Formation 170
Rational design of new competitive inhibitors of human CK2 activity 169
Development of novel pyridazinone-based adenosine receptor ligands 167
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 166
Purinergic P2X receptors: Structural models and analysis of receptor-ligand interaction 162
Highlights on the development of A(2A) adenosine receptor agonists and antagonists 161
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A(3) adenosine receptor 155
Synthesis and biological activity of trisubstituted adenines as A(2A) adenosine receptor antagonists 153
7th Joint Italian-German Purine Club Meeting - “Advances in basic and translational purinergic research” - 20-22 luglio 2017 153
Substituted adenine derivatives as novel P2X3 receptor ligands 149
GTP-Eu binding assay optimization for the adenosine A3 receptor ligands screening 149
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 149
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 149
New purine derivatives as P2X3 receptor antagonists 147
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 146
A2A adenosine receptor ligands: effects on alcohol intake in alcohol-preferring rats 146
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A(3) receptor 143
Letters in Drug Design & Discovery 143
Existence of snoRNA, microRNA, piRNA characteristics in a novel non-coding RNA: x-ncRNA and its biological implication in Homo sapiens 141
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 139
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: Molecular docking analysis and pharmacological studies 136
null 134
Totale 22.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.595
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.595
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021256 0 0 0 0 0 0 0 0 0 0 0 256
2021/20221.488 184 371 33 41 67 66 86 124 111 145 92 168
2022/20231.440 164 103 56 230 137 188 9 74 245 70 109 55
2023/20241.247 161 64 80 49 57 114 65 92 138 44 45 338
2024/20254.107 180 74 330 195 135 258 476 1.025 340 283 277 534
2025/20266.103 367 349 702 813 641 453 1.012 451 400 450 357 108
Totale 25.276